Developer docs
API playgroundTry for free, no card

Search company profiles

Reneo Pharmaceuticals

Full company profile

uuid00023vy

Namestring
Reneo Pharmaceuticals
Legal namestring
Reneo Pharmaceuticals
Websiteurl
reneopharma.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California, focused on developing therapies for patients with orphan metabolic diseases. The company operates as a for-profit, publicly traded entity (previously NASDAQ: RPHM, now delisted) with a headcount of 51-100 employees and a leadership team spanning co-founder/CEO, COO, CFO, CMO, VP of Clinical Operations, and a Head of Patient Engagement and Communications. Its strategic positioning is in the rare disease drug development segment, where orphan drug designation pathways and small, identifiable patient populations are typical competitive dynamics.

Reneo's business model is that of a pre-revenue drug developer: capital is raised through equity financings (including a $95M Series B in December 2020 co-led by Abingworth and Novo Ventures, a $20M round in May 2022, and a $55M public offering with concurrent Abingworth private placement in May 2023) and deployed into research and clinical development of metabolic disease therapeutics. The company has no approved products, no disclosed revenue, and no disclosed pricing model. Its funding base — New Enterprise Associates, Abingworth Bioventures, Novo Ventures, Lundbeckfonden Ventures, Chiesi Ventures, Pappas Capital, RiverVest, Rock Springs Capital, Aisling Capital, and Amzak Health Investors — reflects a syndicate of dedicated life sciences investors.

Financial performance shows deepening operating losses year over year (from roughly -$15M in 2019 toward -$80M+ in 2023), characteristic of a clinical pipeline burning cash against accumulated funding. There is no evidence of commercial partnerships, licensing deals, or revenue-generating collaborations in the input. The combination of pre-revenue status, delisting, widening losses, and absence of disclosed product launches points to a company either in late-stage pipeline development awaiting a catalytic event or in a restructuring/transitional phase. No artificial intelligence or machine learning capabilities are referenced in the available data.

Short descriptiontext

Reneo Pharmaceuticals is a pre-revenue, clinical-stage biopharmaceutical company founded in 2014 and based in San Diego that develops therapies for patients with orphan metabolic diseases. It is funded by dedicated life sciences investors and has no approved products or revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
orphan drug development, metabolic disease therapies, rare disease pharmaceuticals, clinical-stage biotechnology, mitochondrial disease drugs
Industry3 codes
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing32541
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Disease Pharmaceuticals
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for orphan metabolic diseases, including rare genetic mitochondrial and metabolic disorders. The company is pre-revenue and focused on discovering, developing, and advancing its proprietary pipeline of drug candidates through clinical trials targeting conditions of high unmet medical need.

Differentiator
Functional benefit
Problem solved
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioMarin is a global leader in rare metabolic disease therapies (e.g., PKU, MPS), making it the most directly comparable commercial-stage orphan metabolic disease peer for Reneo's pipeline focus.

TypeDirect peer
Description

Travere develops therapies for rare kidney and metabolic diseases, sharing Reneo's orphan-disease, small-cap clinical-to-commercial profile and similar regulatory pathway dynamics.

TypeDirect peer
Description

Ultragenyx develops and commercializes therapies for rare and ultra-rare metabolic diseases, with overlapping indication strategy and similar orphan-drug commercial dynamics as Reneo.

TypeDirect peer
Description

Amicus focuses on rare metabolic diseases including Fabry disease and Pompe disease, with a clinical-stage to commercial orphan-disease pipeline directly comparable to Reneo's model.

5Horizon Therapeutics (Amgen)
TypeBroad incumbent
Description

Horizon Therapeutics, acquired by Amgen, operates a broad rare-disease portfolio with metabolic and endocrine therapies, reflecting the large-pharma orphan-disease M&A pathway available to Reneo as an exit.

TypeDirect peer
Description

BridgeBio targets genetic and rare diseases with a multi-asset R&D model, providing a relevant peer for Reneo's small-molecule approach to inherited metabolic disorders.

TypeBroad incumbent
Description

Alexion, now part of AstraZeneca, is a broad rare-disease franchise with multiple commercial metabolic and enzyme-replacement therapies, representing the strategic-acquisition benchmark for orphan metabolic companies like Reneo.

8Aeglea BioTherapeutics
TypeEmerging player
Description

Aeglea develops engineered human enzymes for rare metabolic diseases, providing a directly comparable enzymatic-therapy approach overlapping with Reneo's orphan metabolic focus.

TypeEmerging player
Description

Crinetics is a clinical-stage company developing therapies for rare endocrine diseases, sharing Reneo's small-molecule rare-disease development model and similar stage of maturity.

TypeEmerging player
Description

Soleno is a clinical-stage rare-disease company focused on metabolic and neurodevelopmental disorders, comparable to Reneo in scale, stage, and orphan-disease regulatory strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Reneo Pharmaceuticals

Rare Disease Pharmaceuticalsreneopharma.com

Reneo Pharmaceuticals is a pre-revenue, clinical-stage biopharmaceutical company founded in 2014 and based in San Diego that develops therapies for patients with orphan metabolic diseases. It is funded by dedicated life sciences investors and has no approved products or revenue.

What Reneo Pharmaceuticals does

Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California, focused on developing therapies for patients with orphan metabolic diseases. The company operates as a for-profit, publicly traded entity (previously NASDAQ: RPHM, now delisted) with a headcount of 51-100 employees and a leadership team spanning co-founder/CEO, COO, CFO, CMO, VP of Clinical Operations, and a Head of Patient Engagement and Communications. Its strategic positioning is in the rare disease drug development segment, where orphan drug designation pathways and small, identifiable patient populations are typical competitive dynamics.

Reneo's business model is that of a pre-revenue drug developer: capital is raised through equity financings (including a $95M Series B in December 2020 co-led by Abingworth and Novo Ventures, a $20M round in May 2022, and a $55M public offering with concurrent Abingworth private placement in May 2023) and deployed into research and clinical development of metabolic disease therapeutics. The company has no approved products, no disclosed revenue, and no disclosed pricing model. Its funding base — New Enterprise Associates, Abingworth Bioventures, Novo Ventures, Lundbeckfonden Ventures, Chiesi Ventures, Pappas Capital, RiverVest, Rock Springs Capital, Aisling Capital, and Amzak Health Investors — reflects a syndicate of dedicated life sciences investors.

Financial performance shows deepening operating losses year over year (from roughly -$15M in 2019 toward -$80M+ in 2023), characteristic of a clinical pipeline burning cash against accumulated funding. There is no evidence of commercial partnerships, licensing deals, or revenue-generating collaborations in the input. The combination of pre-revenue status, delisting, widening losses, and absence of disclosed product launches points to a company either in late-stage pipeline development awaiting a catalytic event or in a restructuring/transitional phase. No artificial intelligence or machine learning capabilities are referenced in the available data.

Reneo Pharmaceuticals firmographics

Firmographics
Name
Reneo Pharmaceuticals
Legal name
Reneo Pharmaceuticals
Website
https://reneopharma.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Reneo Pharmaceuticals is a pre-revenue, clinical-stage biopharmaceutical company founded in 2014 and based in San Diego that develops therapies for patients with orphan metabolic diseases. It is funded by dedicated life sciences investors and has no approved products or revenue.
Ownership category
akta.pro rank

Reneo Pharmaceuticals industry classification

Industry
Product category
Rare Disease Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Orphan drug development
  • Metabolic disease therapies
  • Rare disease pharmaceuticals
  • Clinical-stage biotechnology
  • Mitochondrial disease drugs

Where Reneo Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Reneo Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Reneo Pharmaceuticals product offering

Product offering

Core offering

Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for orphan metabolic diseases, including rare genetic mitochondrial and metabolic disorders. The company is pre-revenue and focused on discovering, developing, and advancing its proprietary pipeline of drug candidates through clinical trials targeting conditions of high unmet medical need.

Differentiator

Problem solved

Functional benefit

Companies that use Reneo Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Reneo Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Reneo Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Reneo Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: BioMarin is a global leader in rare metabolic disease therapies (e.g., PKU, MPS), making it the most directly comparable commercial-stage orphan metabolic disease peer for Reneo's pipeline focus.
  • Travere Therapeutics: Travere develops therapies for rare kidney and metabolic diseases, sharing Reneo's orphan-disease, small-cap clinical-to-commercial profile and similar regulatory pathway dynamics.
  • Ultragenyx Pharmaceutical: Ultragenyx develops and commercializes therapies for rare and ultra-rare metabolic diseases, with overlapping indication strategy and similar orphan-drug commercial dynamics as Reneo.
  • Amicus Therapeutics: Amicus focuses on rare metabolic diseases including Fabry disease and Pompe disease, with a clinical-stage to commercial orphan-disease pipeline directly comparable to Reneo's model.
  • BridgeBio Pharma: BridgeBio targets genetic and rare diseases with a multi-asset R&D model, providing a relevant peer for Reneo's small-molecule approach to inherited metabolic disorders.

Broad incumbents

  • Horizon Therapeutics (Amgen): Horizon Therapeutics, acquired by Amgen, operates a broad rare-disease portfolio with metabolic and endocrine therapies, reflecting the large-pharma orphan-disease M&A pathway available to Reneo as an exit.
  • Alexion (AstraZeneca Rare Disease): Alexion, now part of AstraZeneca, is a broad rare-disease franchise with multiple commercial metabolic and enzyme-replacement therapies, representing the strategic-acquisition benchmark for orphan metabolic companies like Reneo.

Emerging players

  • Aeglea BioTherapeutics: Aeglea develops engineered human enzymes for rare metabolic diseases, providing a directly comparable enzymatic-therapy approach overlapping with Reneo's orphan metabolic focus.
  • Crinetics Pharmaceuticals: Crinetics is a clinical-stage company developing therapies for rare endocrine diseases, sharing Reneo's small-molecule rare-disease development model and similar stage of maturity.
  • Soleno Therapeutics: Soleno is a clinical-stage rare-disease company focused on metabolic and neurodevelopmental disorders, comparable to Reneo in scale, stage, and orphan-disease regulatory strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Reneo Pharmaceuticals social profiles

Digital presence

Reneo Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Reneo Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Reneo Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Reneo Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reneo Pharmaceuticals

What does Reneo Pharmaceuticals do?

Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for orphan metabolic diseases, including rare genetic mitochondrial and metabolic disorders. The company is pre-revenue and focused on discovering, developing, and advancing its proprietary pipeline of drug candidates through clinical trials targeting conditions of high unmet medical need.

Is Reneo Pharmaceuticals a public or private company?

Reneo Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Reneo Pharmaceuticals founded?

Reneo Pharmaceuticals was founded in 2014. It employs 51 to 100 people.

Where is Reneo Pharmaceuticals based?

Reneo Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

Who are Reneo Pharmaceuticals's main competitors?

Direct peers on record are BioMarin Pharmaceutical, Travere Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics and BridgeBio Pharma. Broad incumbents are Horizon Therapeutics (Amgen) and Alexion (AstraZeneca Rare Disease). Emerging players are Aeglea BioTherapeutics, Crinetics Pharmaceuticals and Soleno Therapeutics.

Does Reneo Pharmaceuticals have an API?

No public API is recorded for Reneo Pharmaceuticals.

What industry is Reneo Pharmaceuticals in?

Reneo Pharmaceuticals's product category is Rare Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooDeep Track Capital, LP's Strategic Acquisition in Reneo Pharmaceuticals IncDeep Track Capital, LP acquired 660,136 shares of Reneo Pharmaceuticals at $18.20 per share on October 22, 2024, raising its stake to 5.22%. The biotech firm, which develops treatments for rare mitochondrial diseases, has a market cap of about $60.84 million and a stock price of $18.20.YahooCormorant Asset Management's Strategic Acquisition of Reneo Pharmaceuticals SharesCormorant Asset Management acquired 189,571.7 shares of Reneo Pharmaceuticals on October 4, 2024, at $18.2 per share, a 0.2% portfolio impact. The firm now holds a 14.98% stake in the clinical-stage biotech, which has declined 88.1% since its IPO.BenzingaRecently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst EnthusOppenheimer initiated coverage on OnKure Therapeutics with an Outperform rating following the company's merger with Reneo Pharmaceuticals and a $65 million private placement. The analyst highlighted OKI-219 as a promising third-generation PI3Kα inhibitor for breast cancer, noting its superior selectivity compared to Novartis AG's alpelisib despite some trade-offs in helical mutant targeting.YahooCarlyle Group Inc. Reduces Stake in Reneo Pharmaceuticals Inc.Carlyle Group reduced its stake in Reneo Pharmaceuticals by 261,702 shares on October 8, 2024, leaving 8,194 shares at $18.20 per share. The reduction represents a 96.96% cut from its prior holding, lowering its portfolio stake by 0.45%.BenzingaReneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying - Exicure (NASDAQ:XCUR)The article reports on recent insider stock purchases by significant shareholders and executives at Exicure, Amylyx Pharmaceuticals, and Reneo Pharmaceuticals. These transactions include a $711,669 purchase by DGP Co., Ltd. in Exicure, a $101,368 acquisition by CFO James M Frates in Amylyx, and a $484,344 buy by Braden Michael Leonard in Reneo. The report highlights these trades as indicators of insider confidence despite the companies reporting quarterly losses or entering into debt-for-equity agreements.Investing.comReneo Pharmaceuticals executive buys shares worth over $484k By Investing.comBraden Michael Leonard, a significant shareholder of Reneo Pharmaceuticals, bought over $484,000 worth of common stock in September 2024, purchasing 36,176, 150,000, and 172,747 shares at prices between $1.313 and $1.3966. The company's stock has fallen 82.13% over the past year, and Leonard's indirect holdings increased after the transactions.BenzingaCitizens And 2 Other Penny Stocks Insiders Are Buying - Citizens (NYSE:CIA)Citizens, Reneo Pharmaceuticals, and AN2 Therapeutics insiders bought shares on Aug. 13. Citizens' insider spent $13,994 for 5,126 shares at $2.73, while Reneo's insider bought 271,826 shares at $1.40 and AN2's 10% owner bought 1.5 million at $1.04.PR NewswireSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMMonteverde & Associates PC is investigating Reneo Pharmaceuticals' proposed merger with OnKure. Under the agreement, Reneo shareholders would own approximately 31% of the combined company. The firm offers free information to shareholders.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RPHM, WIRE, BCAL, AIRCHalper Sadeh LLC, an investor rights law firm, announced investigations into four companies for potential federal securities law violations or fiduciary duty breaches related to pending mergers or acquisitions. The investigations cover Reneo Pharmaceuticals' merger with OnKure (with pre-merger Reneo shareholders expected to own ~31% of the combined entity), Encore Wire Corporation's sale to Prysmian for $290.00 per share, Southern California Bancorp's merger with California BanCorp (Southern California shareholders to own ~57.1% of combined company), and Apartment Income REIT Corp.'s sale to Blackstone for $39.12 per share. The law firm is seeking increased consideration, additional disclosures, and other relief on behalf of shareholders, handling cases on a contingent fee basis.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBOW, PRFT, RPHMHalper Sadeh LLC, an investor rights law firm, announced investigations into three pending corporate transactions for potential violations of federal securities laws and breaches of fiduciary duties. The three companies under scrutiny are SilverBow Resources Inc. (sale to Crescent Energy Company), Perficient Inc. (sale to an affiliate of BPEA Private Equity Fund VIII), and Reneo Pharmaceuticals Inc. (merger with OnKure Inc.). The law firm is soliciting affected shareholders to contact them regarding their legal rights and options, indicating potential shareholder litigation against these proposed transactions.